MD

Pediatrix Medical Group, Inc. (10-Q) Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2008. Pediatrix Medical Group, Inc. (PMG) is a national medical group practice providing pediatric and maternal-fetal subspecialty services. The company announced plans to change its name to MEDNAX, Inc. in early 2009 to reflect its expansion beyond pediatric specialties. During the period, PMG completed the acquisition of 10 physician group practices and sold its newborn metabolic screening laboratory business.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 14.6% ($34.1 million) for the quarter and 15.5% ($103.2 million) for the nine months compared to 2007. Approximately 92% of the quarterly increase was attributable to acquisitions.
• Discontinued Operations: The company sold its newborn metabolic screening laboratory in February 2008 for $66.0 million. This resulted in a $22.0 million after-tax gain included in the nine-month net income, significantly boosting the year-to-date bottom line compared to the prior year.
• Operating Expenses: Practice salaries and benefits rose 21.7% for the quarter, driven by new staff for acquisitions. General and administrative expenses were relatively flat for the nine-month period due to the absence of stock option review fees incurred in 2007.
• Liquidity: Cash and cash equivalents dropped from $102.8 million at year-end 2007 to $12.1 million at September 30, 2008. This decrease was driven by $236.4 million in acquisition payments and $200 million in share repurchases, partially offset by borrowings.
• Debt: The company replaced its $225 million credit facility with a new $350 million revolving line of credit in September 2008. As of the reporting date, $171.0 million was outstanding.

Guidance, Outlook, and Risks

• Outlook: Management anticipates an effective tax rate of approximately 39.25% for the full year 2008. The company expects funds from operations and its credit facility to be sufficient for working capital and acquisitions for the next 12 months.
• Strategic Shift: The name change to MEDNAX, Inc. signals a strategic pivot to a broader national medical group practice model.
• Legal and Regulatory Risks:
  • SEC Investigation: The SEC has commenced a formal investigation into the company's historical stock option granting practices. The company is cooperating fully.
  • Corporate Integrity Agreement: PMG is subject to a five-year agreement with the Office of Inspector General (OIG) regarding billing practices. Failure to comply could result in exclusion from federal healthcare programs.
  • Credit Market Disruptions: The filing highlights risks associated with potential disruptions in capital and credit markets, which could affect the availability of funds under the Line of Credit.
• Unusual Items: The nine-month results include a significant one-time gain from the sale of the laboratory business. Conversely, 2007 results included costs related to stock option reviews and 409A tax obligations that are not present in the current period.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing SEC investigation into stock option practices.
• Confirm compliance with the Corporate Integrity Agreement and monitor for any new government audits or penalties.
• Assess the sustainability of revenue growth excluding the impact of recent acquisitions.
• Monitor the company's ability to maintain liquidity given the significant reduction in cash reserves and reliance on the Line of Credit.
• Review the integration progress of the 10 physician practices acquired in the first nine months of 2008.